Furthermore, the GPNMB levels of the TNBC group were also higher than those of the DCIS group (P = 0.0459), as shown in Figure2C. There were at least 11 patients with >15 ng/mL of GPNMB, including nine (8.3%) BC patients (two Luminal, five HER2-positive, and two TNBC cases), one (2%) CC patient (stage II), and one (3.2%) GC patient (stage I). This evidence concerns the gene ERBB2 and ductal breast carcinoma in situ.